Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.31B |
| Gross Profit (TTM) | $322.09M |
| EBITDA | $125.57M |
| Operating Margin | 11.40% |
| Return on Equity | 16.20% |
| Return on Assets | 10.10% |
| Revenue/Share (TTM) | $15.87 |
| Book Value | $5.66 |
| Price-to-Book | 4.45 |
| Price-to-Sales (TTM) | 1.48 |
| EV/Revenue | 1.375 |
| EV/EBITDA | 15.29 |
| Quarterly Earnings Growth (YoY) | 78.90% |
| Quarterly Revenue Growth (YoY) | 5.30% |
| Shares Outstanding | $76.73M |
| Float | $70.15M |
| % Insiders | 2.00% |
| % Institutions | 111.36% |
Volatility is currently expanding
IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.
Progyny NASDAQ: PGNY reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.
JBHT, PGNY, BSET, VSXY and PARR stand out for relative price strength, positive estimate revisions and solid fundamentals amid market uncertainty.
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGNY and any ticker you trade — then tracks every position and per-strategy win rate.
